Last reviewed · How we verify
NCT06063733
Development and Feasibility Testing of Digital Theory-based Pursed Lip Breathing in Stable Patients With COPD
NA trial testing Digital pursed lip breathing intervention in Pulmonary Disease, Chronic Obstructive in 15 participants. Status unknown.
20 April 2024
Quick facts
| Lead sponsor | Manchester Metropolitan University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 15 |
| Start date | 30 October 2023 |
| Primary completion | 20 April 2024 |
| Estimated completion | 20 April 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Digital pursed lip breathing intervention
Conditions studied
- Pulmonary Disease, Chronic Obstructive — all drugs for Pulmonary Disease, Chronic Obstructive →
Sponsor
Manchester Metropolitan University
Who can join
Eligibility, any sex, with Pulmonary Disease, Chronic Obstructive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this pre-post design clinical trial is to develop a digital, theory-based Pursed Lip Breathing intervention protocol software system installed on smartphones (DT-PLB) and to preliminarily evaluate its feasibility and effects in stable Chronic Obstructive Pulmonary Disease (COPD). The main objectives are: 1. To develop a digital, theory-based Pursed Lip Breathing intervention protocol software system installed on smartphones for managing breathing exercises in stable COPD patients. 2. To pilot the methodological procedures of the pre-post study. 3. To determine the recruitment rate, retention rate, attrition rate, and software usage compliance during the subject recruitment and follow-up process of the pre-post study. 4. To evaluate the perception and satisfaction of COPD patients using the DT-PLB. 5. To preliminarily examine the effects of using the DT-PLB intervention on COPD patients, including the six-minute walking test, FEV1% predicted, FEV1/FVC, mMRC scale, COPD assessment test scale, and health points. 6. To identify any potential adverse events associated with the implementation of DT-PLB. Participants will perform the following tasks during the intervention: 1. Register a personal account on the DT-PLB software. 2. Acquire knowledge and skills related to Pursed Lip Breathing by watching instructional videos. 3. Practice Pursed Lip Breathing for 10 minutes per session, three times daily for eight weeks, as per reminders and guidance provided by the software. 4. Earn health points by completing specific actions as instructed. 5. Optionally post individual texts on the peer forum for peer support within the DT-PLB software. 6. Complete two outcome assessments as scheduled.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Digital gamification-based pursed lip breathing exercises driven by Behaviour Change Wheel in patients with COPD: a feasibility trial protocol using pre-post study design.
Huang H, Liu F, Mohammad M, Watson R, et al · · 2025 · PMID 40147988 · DOI 10.1136/bmjopen-2024-090832
Verify or expand the search:
- PubMed search for NCT06063733
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pulmonary Disease, Chronic Obstructive
Currently open trials in the same condition.
- NCT07177339 — eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (CO · Phase 3 · recruiting
- NCT06961214 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
- NCT06959095 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
- NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
- NCT06712563 — Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting · recruiting
Other Manchester Metropolitan University trials
Trials by the same sponsor.
- NCT07535996 — IBM Dietary Surveillance Study · not yet recruiting
- NCT06827691 — Heat Therapy and Peripheral Artery Disease · NA · not yet recruiting
- NCT06624774 — Prehabilitation's Effect on Skeletal Muscle Mass in Cardiac Patients · NA · active not recruiting
- NCT05784272 — Determinants of Progression From Phase III to IV Cardiac Rehabilitation · unknown
- NCT05588479 — Pomegranate Extract and Inflammageing · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06063733 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Manchester Metropolitan University
- Last refreshed: 2 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06063733.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing